Overview

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Status:
Completed
Trial end date:
2019-07-27
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
Phase:
Phase 2
Details
Lead Sponsor:
AzurRx BioPharma, Inc.